Evidence map›Paper›PMID 21788457›Full record

ArticleAntimicrobial agents and chemotherapy2011

Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.

Molly E Steed, Celine Vidaillac, Warren E Rose, Patricia Winterfield, Glenn W Kaatz, Michael J Rybak

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Mechanisms of drug resistance: daptomycin resistance.Annals of the New York Academy of Sciences · 2015
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Molly E SteedAnti-Infective Research Laboratory, Pharmacy Practice - 4148, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, USA.
Celine Vidaillac
Warren E Rose
Patricia Winterfield
Glenn W Kaatz
Michael J Rybak
Wayne State University · USEugene Applebaum College of Pharmacy and Health Sciences · USUniversity of Wisconsin–Madison · US

Funding

Impact of Daptomycin Dose Exposure on Enterococci and Characterization of ResistaR21AI092055 · NIAID · WAYNE STATE UNIVERSITY · PI RYBAK, MICHAEL JOSEPH · 2011 to 2012
$430k
NIAID NIH HHS R21 AI092055
6 · The paper itself

Abstract

Two daptomycin (DAP) regimens were evaluated in a pharmacokinetic/pharmacodynamic (PK/PD) model, and the mutants recovered were examined for changes in phenotypic characteristics. Three Enterococcus faecium strains (vancomycin-resistant Enterococcus [VRE] ATCC 51559, VRE 12311, and VRE SF 12047) were utilized in a 7-day, 1-compartment in vitro PK/PD model. The simulated dosing regimens were DAP at 6 mg/kg/day (free C(max) [fC(max)] = 7.9 μg/ml, half-life [t(1/2)] = 8 h) and DAP at 10 mg/kg/day (fC(max) = 13.17 μg/ml, t(1/2) = 8 h). Samples were plated daily on Mueller-Hinton agar containing DAP at 16 μg/ml and 50 mg/liter Ca(2+) to assess the emergence of DAP resistance. For each strain, the mutant with the highest DAP MIC was then evaluated for changes in relative surface charge, cell wall thickness, and cytoplasmic membrane depolarization induced by DAP. The initial DAP MICs were 4 μg/ml for all 3 strains. A dose-dependent response and regrowth were observed for DAP 6 mg/kg/day and DAP 10 mg/kg/day against all 3 strains. Mutants of VRE ATCC 51559 (MIC = 128 and 64 μg/ml) and VRE 12311 (MIC = 256 and 32 μg/ml) were recovered from the DAP 6 mg and DAP 10 mg regimen, respectively. For VRE SF 12047, a mutant (MIC = 64 μg/ml) was recovered from the DAP 6 mg model. All mutants displayed an increase in relative surface charge compared to those of their respective parent strains. The DAP-resistant mutants displayed a 43 to 58% increase in cell wall thickness (P < 0.0001), while DAP membrane depolarization decreased by 53 to 65% compared to that of the susceptible strains. VRE with DAP resistance displayed increased surface charge, increased cell wall thickness, and decreased depolarization induced by DAP, consistent with previous observations in Staphylococcus aureus with reduced DAP susceptibility. Further characterization of DAP-resistant VRE is warranted.

Indexed as

Vancomycin ResistanceAminoacyltransferasesAnti-Bacterial AgentsBacterial ProteinsCell MembraneCell WallDaptomycinDrug Resistance, BacterialEnterococcusMembrane PotentialsMicrobial Sensitivity TestsPhenotypeStaphylococcus aureusVancomycinAminoacyltransferasesAnti-Bacterial AgentsBacterial ProteinsDaptomycinmprF protein, Staphylococcus aureusVancomycin

Identifiers

PMID21788457
PMCPMC3186956
OpenAlexW2140179838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.